MT-302 Utilizes Novel Mechanism of Action to Offer a Unique Treatment in Epithelial Tumors
Rasha Cosman, BSc, MBBS, FRACP, and Charlotte Lemech, MBBS, discuss the phase 1 MYE Symphony study (NCT05969041) of MT-302 in advanced or metastatic epithelial cancers.
Dr Cosman on the Potential Utility of MT-302 in TROP-2–Expressing Epithelial Cancers
Rasha Cosman, BSc, MBBS, FRACP, discusses the mechanism of action and potential role for the in vivo mRNA CAR therapy MT-302 in TROP-2–expressing epithelial cancers.
MT-302 Under Investigation in Advanced or Metastatic Epithelial Tumors
Charlotte Lemech, MBBS, discusses the mechanism of action of MT-302, as well as the aims of the MYE Symphony trial and its potential future implications.
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
